Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
RLAY Stock Forecast 2026-2027
$8.07
Current Price
$1.40B
Market Cap
Buy 11
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to RLAY Price Targets
+135.4%
To High Target of $19.00
+79.7%
To Median Target of $14.50
+48.7%
To Low Target of $12.00
RLAY Price Momentum
+0.9%
1 Week Change
-4.8%
1 Month Change
+111.8%
1 Year Change
-4.6%
Year-to-Date Change
-10.7%
From 52W High of $9.04
+354.6%
From 52W Low of $1.78
๐ TOP ANALYST CALLS
Did RLAY Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if Relay Therapeutics is one of their latest high-conviction picks.
Latest RLAY Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, RLAY has a bullish consensus with a median price target of $14.50 (ranging from $12.00 to $19.00). The overall analyst rating is N/A (N/A/10). Currently trading at $8.07, the median forecast implies a 79.7% upside. This outlook is supported by 11 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Dane Leone at Raymond James, projecting a 135.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RLAY Analyst Ratings
11
Buy
1
Hold
0
Sell
RLAY Price Target Range
Low
$12.00
Average
$14.50
High
$19.00
Current: $8.07
Latest RLAY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RLAY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 12, 2025 | Wells Fargo | Eva Fortea Verdejo | Overweight | Upgrade | $13.00 |
| Nov 7, 2025 | Wells Fargo | Eva Fortea Verdejo | Equal-Weight | Maintains | $6.00 |
| Sep 4, 2025 | Guggenheim | Brad Canino | Buy | Assumes | $15.00 |
| Aug 26, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $14.00 |
| Aug 8, 2025 | Raymond James | Dane Leone | Strong Buy | Maintains | $19.00 |
| May 7, 2025 | Guggenheim | Michael Schmidt | Buy | Maintains | $10.00 |
| Apr 17, 2025 | Wells Fargo | Equal-Weight | Initiates | $4.00 | |
| Mar 7, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $16.00 |
| Feb 27, 2025 | Goldman Sachs | Salveen Richter | Buy | Maintains | $18.00 |
| Feb 27, 2025 | Stifel | Bradley Canino | Buy | Maintains | $23.00 |
| Jan 14, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $16.00 |
| Dec 12, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $21.00 |
| Dec 5, 2024 | Leerink Partners | Outperform | Maintains | $N/A | |
| Dec 4, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $16.00 |
| Dec 4, 2024 | Leerink Partners | Christopher Liu | Outperform | Maintains | $18.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $20.00 |
| Oct 14, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $19.00 |
| Sep 17, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $21.00 |
| Sep 16, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $19.00 |
| Sep 16, 2024 | Stifel | Bradley Canino | Buy | Reiterates | $28.00 |
Relay Therapeutics Inc. (RLAY) Competitors
The following stocks are similar to Relay Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Relay Therapeutics Inc. (RLAY) Financial Data
Relay Therapeutics Inc. has a market capitalization of $1.40B with a P/E ratio of -3.4x. The company generates $8.36M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -100.0% quarter-over-quarter, while maintaining an operating margin of -3,887.3% and return on equity of -41.1%.
Valuation Metrics
Market Cap
$1.40B
Enterprise Value
$788.81M
P/E Ratio
-3.4x
PEG Ratio
0.1x
Price/Sales
161.8x
Growth & Margins
Revenue Growth (YoY)
-100.0%
Gross Margin
N/A
Operating Margin
-3,887.3%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+42.6%
Current Ratio
19.1x
Debt/Equity
5.5x
ROE
-41.1%
ROA
-25.4%
๐ก SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Relay Therapeutics Inc. (RLAY) Business Model
About Relay Therapeutics Inc.
What They Do
Biotechnology company focused on drug discovery.
Business Model
Relay Therapeutics generates revenue by developing targeted therapeutics for complex diseases, primarily in oncology and genetic disorders. They utilize innovative technologies such as dynamic protein motion analysis to create more effective treatments, enhancing their market position in the competitive biotech industry.
Additional Information
The company aims to revolutionize personalized medicine by tailoring treatments to individual patient profiles, improving healthcare outcomes. Their commitment to addressing complex diseases through advanced research positions them as a key player in the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
188
CEO
Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS
Country
United States
IPO Year
2020
Website
www.relaytx.comRelay Therapeutics Inc. (RLAY) Latest News & Analysis
Latest News
Quick Summary
Relay Therapeutics reported consistent efficacy data for zovegalisib (RLY-2608) in treating PI3Kฮฑ-mutated, HR+/HER2- metastatic breast cancer, with 10.3-month median PFS overall. Phase 3 trial ongoing.
Why It Matters
Efficacy data showing sustained median progression-free survival (PFS) in key patient groups enhances Relay Therapeutics' potential market position and may attract investor interest in its innovative therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Commodore Capital increased its position in RLAY by 3.65 million shares in Q3, representing 0.7% of its 13F assets under management.
Why It Matters
Commodore Capital's significant increase in RLAY shares may signal strong confidence in the company's potential, influencing investor sentiment and stock performance.
Source: The Motley Fool
Market Sentiment:
Positive
Relay Therapeutics Director Sells $300,000 Worth of Shares. Here's Why Investors Shouldn't Panic.
1 month ago
Quick Summary
Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, sold over 40,000 shares in October for approximately $300,000, partly due to company policy on vested stock units.
Why It Matters
Peter Rahmer's sale of 40,000 shares may signal potential insider sentiment about the company's outlook, influencing investor confidence and stock price movements.
Source: The Motley Fool
Market Sentiment:
Negative
Relay Therapeutics, Inc. (RLAY) Presents at Jefferies London Healthcare Conference 2025 Transcript
1 month ago
Quick Summary
Relay Therapeutics, Inc. (RLAY) will present at the Jefferies London Healthcare Conference on November 19, 2025, featuring CEO Sanjiv Patel and Chief Corporate Development Officer Peter Rahmer.
Why It Matters
Relay Therapeutics' participation in a major healthcare conference could signal upcoming developments or insights into their pipeline, impacting stock sentiment and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Relay Therapeutics continues clinical trials for RLY-2608 in breast cancer and vascular malformations, added experienced board members, and reported $596 million in cash at Q3 2025.
Why It Matters
Relay Therapeutics' advancements in clinical trials and strong cash position signal potential growth, while adding seasoned directors enhances commercialization prospects, attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Relay Therapeutics, Inc. (Nasdaq: RLAY) will participate in Guggenheim's 2nd Annual Healthcare Innovation Conference on November 10, 2025, from 11:00 to 11:25 a.m.
Why It Matters
Relay Therapeutics' participation in key healthcare conferences can signal progress in its development pipeline, potentially influencing stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About RLAY Stock
What is Relay Therapeutics Inc.'s (RLAY) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, Relay Therapeutics Inc. (RLAY) has a median price target of $14.50. The highest price target is $19.00 and the lowest is $12.00.
Is RLAY stock a good investment in 2026?
According to current analyst ratings, RLAY has 11 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.07. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RLAY stock?
Wall Street analysts predict RLAY stock could reach $14.50 in the next 12 months. This represents a 79.7% increase from the current price of $8.07. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Relay Therapeutics Inc.'s business model?
Relay Therapeutics generates revenue by developing targeted therapeutics for complex diseases, primarily in oncology and genetic disorders. They utilize innovative technologies such as dynamic protein motion analysis to create more effective treatments, enhancing their market position in the competitive biotech industry.
What is the highest forecasted price for RLAY Relay Therapeutics Inc.?
The highest price target for RLAY is $19.00 from Dane Leone at Raymond James, which represents a 135.4% increase from the current price of $8.07.
What is the lowest forecasted price for RLAY Relay Therapeutics Inc.?
The lowest price target for RLAY is $12.00 from at , which represents a 48.7% increase from the current price of $8.07.
What is the overall RLAY consensus from analysts for Relay Therapeutics Inc.?
The overall analyst consensus for RLAY is bullish. Out of 15 Wall Street analysts, 11 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $14.50.
How accurate are RLAY stock price projections?
Stock price projections, including those for Relay Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 4:09 AM UTC